Increased risk of second lung cancer in Hodgkin's lymphoma survivors: A meta-analysis

Lung

Volumn 191, Issue 1, 2013, Pages 117-134

  Ibrahim, Ezzeldin M ^a   Kazkaz, Ghieth A ^a   Abouelkhair, Khaled M ^a   Al Mansour, Mubarak M ^b   Al Fayea, Turki M ^b   Al Foheidi, Meteb ^b   Bayer, Ali M ^a   Elmasri, Osama A ^a  

^a International Medical Center   (Saudi Arabia)

^b KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Hodgkin's lymphoma; Lung cancer; Second neoplasm

Indexed keywords

ALKYLATING AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CANCER SURVIVOR; FOLLOW UP; GENDER; HODGKIN DISEASE; HUMAN; LUNG CANCER; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; SMOKING;

ADOLESCENT; ADULT; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; SURVIVORS; YOUNG ADULT;

EID: 84873093900     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9418-4     Document Type: Article

References (59)

1. Herbst C, Rehan FA, Skoetz N, Bohlius J, Brillant C, Schulz H, Monsef I, Specht L, Engert A (2011) Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev (2):CD007110. doi: 10.1002/14651858.CD007110.pub2
2. Rathore B, Kadin ME (2010) Hodgkin's lymphoma therapy: past, present, and future. Expert Opin Pharmacother 11(17):2891-2906. doi: 10.1517/14656566.2010. 515979
3. Evens AM, Hutchings M, Diehl V (2008) Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 5(9):543-556. doi: 10.1038/ncponc1186
4. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD Jr, Chauvenet AR (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 15(8):2769-2779
5. Canellos GP (1975) Letter: second malignancies complicating Hodgkin's disease in remission. Lancet 1(7919):1294
6. Baxi SS, Matasar MJ (2010) State-of-the-art issues in Hodgkin's lymphoma survivorship. Curr Oncol Rep 12(6):366-373. doi: 10.1007/s11912-010-0123-2
7. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C, Cavalieri E, Diehl V, Eghbali H, Ferme C, Henry-Amar M, Hoppe R, Howard S, Meyer R, Niedzwiecki D, Pavlovsky S, Radford J, Raemaekers J, Ryder D, Schiller P, Shakhtarina S, Valagussa P, Wilimas J, Yahalom J (2006) Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 17(12):1749-1760. doi: 10.1093/annonc/mdl302
8. Henderson TO, Amsterdam A, Bhatia S, Hudson MM, Meadows AT, Neglia JP, Diller LR, Constine LS, Smith RA, Mahoney MC, Morris EA, Montgomery LL, Landier W, Smith SM, Robison LL, Oeffinger KC (2010) Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 152(7):444-455; W144-454. doi: 10.1059/0003-4819-152-7-201004060-00009
9. Ibrahim EM, Abouelkhair KM, Kazkaz GA, Al-Masri OA, Al-Foheidi M (2012) Risk of second breast cancer in female Hodgkin's lymphoma survivors: a meta-analysis. BMC Cancer 12:197
10. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P (2011) Strengthening the reporting of observational studies in epidemiology-molecular epidemiology (STROBE-ME): an extension of the STROBE statement. PLoS Med 8(10):e1001117. doi: 10.1371/journal.pmed.1001117
11. Clayton D, Hills M (1993) Statistical models in epidemiology. Oxford University Press, Oxford
12. Alder N, Fenty J, Warren F, Sutton AJ, Rushton L, Jones DR, Abrams KR (2006) Meta-analysis of mortality and cancer incidence among workers in the synthetic rubber-producing industry. Am J Epidemiol 164(5):405-420. doi: 10.1093/aje/kwj252
13. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539-1558. doi: 10.1002/sim.1186
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557-560. doi: 10.1136/bmj.327. 7414.557327/7414/557
15. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177-188. doi: 10.1016/0197-2456(86)90046-2
16. Donders AR, van der Heijden GJ, Stijnen T, Moons KG (2006) Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 59(10):1087-1091. doi: 10.1016/j.jclinepi.2006.01.014
17. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629-634
18. List AF, Doll DC, Greco FA (1985) Lung cancer in Hodgkin's disease: association with previous radiotherapy. J Clin Oncol 3(2):215-221
19. Coleman MP, Bell CM, Fraser P (1987) Second primary malignancy after Hodgkin's disease, ovarian cancer and cancer of the testis: a population-based cohort study. Br J Cancer 56(3):349-355
20. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318(2):76-81. doi: 10.1056/NEJM198801143180203
21. Henry-Amar M (1992) Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 3(Suppl 4):117-128
22. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R (1994) Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 12(2):312-325
23. Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts KB, Farber LR, Kiehl RK, Cardinale J, Cooper DL (1996) Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 14(9):2435-2443
24. Hoppe RT (1997) Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8(Suppl 1):115-118
25. Munker R, Grutzner S, Hiller E, Aydemir U, Enne W, Dietzfelbinger H, Busch M, Haas R, Emmerich B, Schmidt M, Duhmke E, Holzel D, Wilmanns W (1999) Second malignancies after Hodgkin's disease: the Munich experience. Ann Hematol 78(12):544-554
26. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van't Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB (2000) Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18(12):2435-2443
27. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC (2000) Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18(3):498-509
28. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM (2000) Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18(3):487-497
29. Cellai E, Magrini SM, Masala G, Alterini R, Costantini AS, Rigacci L, Olmastroni L, Papi MG, Spediacci MA, Innocenti F, Bellesi G, Ferrini PR, Biti G (2001) The risk of second malignant tumors and its consequences for the overall survival of Hodgkin's disease patients and for the choice of their treatment at presentation: analysis of a series of 1524 cases consecutively treated at the Florence University Hospital. Int J Radiat Oncol Biol Phys 49(5):1327-1337
30. Varady E, Deak B, Molnar ZS, Rosta A, Schneider T, Esik O, Eckhardt S (2001) Second malignancies after treatment for Hodgkin's disease. Leuk Lymphoma 42(6):1275-1281. doi: 10.3109/10428190109097752
31. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20(16):3484-3494. doi: 10.1200/jco.2002.09.038
32. Foss AA, Andersen A, Nome O, Jacobsen AB, Holte H, Foss Abrahamsen J, Kvaløy S (2002) Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 13(11):1786-1791. doi: 10.1093/annonc/mdf289
33. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100(6):1989-1996. doi: 10.1182/blood-2002-02-0634
34. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, DeLaat C, Fossati-Bellani F, Morgan E, Oberlin O, Reaman G, Ruymann FB, Tersak J, Meadows AT (2003) High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 21(23):4386-4394. doi: 10.1200/jco.2003.11.059
35. Behringer K, Josting A, Schiller P, Eich HT, Bredenfeld H, Diehl V, Engert A (2004) Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 15(7):1079-1085. doi: 10.1093/annonc/mdh273
36. Petrakova K, Koukalova H, Soumarova R, Palacova M, Blazkova S, Vyzula R (2004) Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT {±} "non risk RT" for Hodgkin's disease (HD). In: ASCO meeting abstracts, vol 22(14-suppl), p 6695
37. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 117(6):1806-1816. doi: 10.1182/blood-2010-04-278796
38. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister TA, Radford JA, Rohatiner AZ, Linch DC (2011) Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 29(31):4096-4104. doi: 10.1200/jco.2011.34.8268
39. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
40. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
41. Weiss W (1997) Cigarette smoking and lung cancer trends. A light at the end of the tunnel? Chest 111(5):1414-1416
42. Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rohatiner AZ, Vaughan Hudson G, Williams MV, Linch DC (2001) Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 19(6):1610-1618
43. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94(3):182-192
44. Kodama K, Ozasa K, Okubo T (2012) Radiation and cancer risk in atomic-bomb survivors. J Radiol Prot 32(1):N51-N54. doi: 10.1088/0952-4746/32/1/ n51
45. Davis FG, Boice JD Jr, Kelsey JL, Monson RR (1987) Cancer mortality after multiple fluoroscopic examinations of the chest. J Natl Cancer Inst 78(4):645-652
46. van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JM, Somers R (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87(20):1530-1537
47. Kaldor JM, Day NE, Bell J, Clarke EA, Langmark F, Karjalainen S, Band P, Pedersen D, Choi W, Blair V et al (1992) Lung cancer following Hodgkin's disease: a case-control study. Int J Cancer 52(5):677-681
48. Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA (1992) Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 304(6835):1137-1143
49. Swerdlow AJ, Barber JA, Horwich A, Cunningham D, Milan S, Omar RZ (1997) Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer 75(1):116-123
50. Hayat MJ, Howlader N, Reichman ME, Edwards BK (2007) Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12(1):20-37. doi: 10.1634/theoncologist.12-1-20
51. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539-4544. doi: 10.1200/jco.2005.04.4859
52. Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R, Hudson M, Greenberg M, Mertens AC (2002) Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA 287(14):1832-1839. doi: joc11569 [pii]
53. Emmons K, Li FP, Whitton J, Mertens AC, Hutchinson R, Diller L, Robison LL (2002) Predictors of smoking initiation and cessation among childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 20(6):1608-1616
54. Freyer DR (2010) Transition of care for young adult survivors of childhood and adolescent cancer: rationale and approaches. J Clin Oncol 28(32):4810-4818. doi: 10.1200/JCO.2009.23.4278
55. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395-409. doi: 10.1056/NEJMoa1102873
56. Hodgson DC (2011) Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011:323-329. doi: 10.1182/asheducation-2011.1.323
57. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JW, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M (2007) Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 357(19):1916-1927. doi: 10.1056/NEJMoa064601
58. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sokler M, Ho A, Rank A, Ganser A, Trumper L, Bokemeyer C, Kirchner H, Schubert J, Kral Z, Fuchs M, Muller-Hermelink HK, Muller RP, Diehl V (2010) Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363(7):640-652. doi: 10.1056/NEJMoa1000067
59. Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80(1):199-205. doi: 10.1016/j.ijrobp.2010.09.007